# Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

> **NCT00171873** · PHASE3 · COMPLETED · sponsor: **Carmen Schade-Brittinger** · enrollment: 85 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Octreotide LAR (Long-acting release)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00171873
- **Lead sponsor:** Carmen Schade-Brittinger
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2008-06
- **Final completion:** 2013-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00171873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00171873, "Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00171873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*